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Over the last years, many microRNAs (miRNAs) have been identified that regulate the 
formation of bioactive lipid mediators such as prostanoids and leukotrienes. Many 
of these miRNAs are involved in complex regulatory circuits necessary for the fine-
tuning of biological functions including inflammatory processes or cell growth. A better 
understanding of these networks will contribute to the development of novel therapeutic 
strategies for the treatment of inflammatory diseases and cancer. In this review, we 
provide an overview of the current knowledge of miRNA regulation in eicosanoid pathways 
with special focus on novel miRNA functions and regulatory circuits of leukotriene and 
prostaglandin biosynthesis.
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INTRODUCTION
MicroRNAs (miRNAs) are a family of small non-coding RNAs that regulate a wide range of 
biological processes including cancer development (Garzon et al., 2006; Croce, 2009; Ochs et al., 
2014). In 1993, lin-4 was the first miRNA to be discovered in the nematode Caenorhabditis elegans 
(C. elegans) and it was found to regulate the gene lin-14 on the post-transcriptional level during 
C. elegans development (Wightman et al., 1993). Later, a second small miRNA involved in worm 
development, let-7, was identified (Reinhart et al., 2000). However, at the time of discovery, it 
was assumed that these RNAs were rare exceptions and only present in nematodes. In 2001, three 
independent publications reported the existence of several hundreds of these small non-coding 
RNAs not only in nematodes but also in murine and human cells (Lagos-Quintana et al., 2001; 
Lau et al., 2001; Lee and Ambros, 2001). Currently, more than 2,500 human miRNAs have been 
identified (http://www.mirbase.org), although the functions of many of them are still unknown. 
In this review, we will give a short overview of novel miRNA functions involved in inflammatory 
processes. Moreover, we summarize the recent findings on miRNAs regulating key enzymes of the 
eicosanoid signaling pathway.
BIOGENESIS AND FUNCTIONS OF MIRNAs
MiRNAs are transcribed from genes as long primary transcripts (pri-miRNAs) mostly by RNA 
polymerase II. In the nucleus, these pri-miRNAs are subsequently cleaved by the endonuclease 
Drosha. Drosha generates about 70 nucleotide (nt) long precursors (pre-miRNAs) that form 
imperfect stem-loop structures. Pre-miRNAs are transported out of the nucleus by exportin-5. In 
the cytoplasm, they are subsequently processed by a multiprotein complex including the RNAse 
III Dicer, Argonaute 2 (AGO2), and trans-activation-responsive RNA-binding protein (TRBP) to 
cleave the RNA into short 21–24 nt miRNA duplexes. Only one strand of the duplex is incorporated 
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into a ribonucleoprotein complex, known as RNA-induced 
silencing complex (RISC). The passenger strand is mostly rapidly 
degraded. The miRNAs are then directed to their binding sites, 
which are usually located in the 3′ untranslated region (UTR) 
of their target messenger RNA (mRNA). Subsequently, they 
mediate endonucleotic cleavage, translational repression, or 
deadenylation of the mRNA transcript, followed by decapping 
and degradation of the target mRNA (Filipowicz et al., 2008) 
(Figures 1A, B). Of note, 40% of the currently known miRNAs 
are located within introns (mirtrons) and are processed by the 
spliceosome in an alternative way (Kim and Kim, 2007; De Rie 
et al., 2017).
Traditionally, it has been assumed that miRNAs are loaded 
into RISC and bind to their target mRNA through specific 
base pairing and that they reduce gene expression at the post-
transcriptional level as their sole canonical function. However, 
there is recent evidence that miRNAs are also able to activate 
gene expression via a non-canonical mechanism (Figures 1C, D). 
miRNAs can bind to RNA-binding proteins (RBPs) and sequester 
them from their target mRNAs in a RISC-independent manner. 
This was shown for miR-328, which acts as an RNA decoy for 
the heterogeneous nuclear ribonucleoprotein E2 (hnRNP E2), 
a global post-transcriptional regulator (Eiring et al., 2010; Saul 
et  al., 2016) (Figure 1C). As a consequence, hnRNP E2 target 
gene expression is activated.
Recent findings demonstrate that cells can secrete bioactive 
molecules (like proteins, lipids, or nucleic acids) from cell to 
cell via extracellular vesicles. Those vesicles can be divided into 
small extracellular vesicles (sEVs, also known as exosomes), 
microvesicles or apoptotic vesicles distinguished by their size 
(Thery et al., 2018). Although these extracellular particles were 
traditionally considered to be a “disposal system” for unnecessary 
membrane proteins (Johnstone et al., 1991), they have now 
captured the interest of researchers as part of the cell to cell 
communication (Wen et al., 2017).
In fact, sEVs (<200 nm) are highly concentrated with miRNAs 
(Goldie et al., 2014). Different cell types, including immune and 
cancer cells, are capable of secretion and uptake of extracellular 
miRNAs from sEVs. This suggests that sEVs could be part of 
the intercellular communication and carry out novel biological 
functions. Since the extracellular miRNA content does not 
necessarily reflect the cellular miRNA profile of the recipient 
cell (Zhang et al., 2015), the functional analysis of sEV-delivered 
miRNAs is an interesting subject. In a study focusing on non-
canonical miRNA functions, which are receptor-mediated, it was 
demonstrated that two sEV-delivered miRNAs, miR-21 and miR-
29a, are able to bind to the murine toll-like receptor (TLR) 7 and 
the human TLR8 and induce cytokine expression (Fabbri et al., 
2012). Similar results were found for miRNA let-7b in the context 
of the nervous system. Extracellular let-7b activates murine TLR7 
and induces neurodegeneration. This observation is of particular 
interest because let-7b has been detected in the cerebrospinal fluid 
of patients with Alzheimer´s disease (Lehmann et al., 2012). Thus, 
sorting of miRNAS into EV and the interaction of EV-delivered 
miRNAs with target cell components such as certain receptors 
seems to be an important way of cell–cell communication.
FIGURE 1 | Overview of miRNA functions. The mature miRNA can be incorporated into the RNA-induced silencing complex (RISC) and binds to its target mRNA 
(A) to repress translation or (B) to induce mRNA degradation—for example, endonucleolytic cleavage. (C) miRNAs can act as RNA decoy to RNA-binding proteins, 
such as miR-328 to hnRNP E2 or miR-574-5p to CUGBP1. (D) miRNAs can be recognized by toll-like receptors 7/8, like miR-21 and miR-29a.
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An interesting aspect for further investigations in this context 
is to explore how miRNAs are sorted into EVs. Initial studies 
demonstrated that miRNAs are specifically recognized by RBPs, 
such as hnRNP A2/B1 and Y-box protein 1 (YBX1). Those RBPs 
bind sequence-specifically to miRNAs and load them selectively 
into sEVs (Villarroya-Beltri et al., 2013; Shurtleff et al., 2016). These 
data suggest that the loading of miRNAs into EV is a specific process 
that might control biological processes such as immune functions.
MIRNAS AND EICOSANOIDS
Eicosanoids such as prostaglandins and leukotrienes are 
biologically active lipid mediators that are products of a local 
cell type-specific arachidonic acid (AA) metabolism (Figure 2). 
Such lipid mediators play a critical role in different pathological 
processes like inflammation and cancer (Zeldin, 2001; Wang and 
Dubois, 2010; Radmark et al., 2015). The synthesis of eicosanoids 
FIGURE 2 | Schematic overview of the leukotriene and prostanoid biosynthesis pathway. Arachidonic acid (AA) is released from cellular membranes 
by cytosolic phospholipase A2 (PLA2). The free AA can further be converted to different leukotrienes (LT). 5-LO is crucial for the conversion of AA to 
5(S)-hydroperoxyeicosatetraenoic acid (5-HPETE) and LTA4. LTA4 is further converted to LTB4 by LTA4 hydrolase (LTA4H) or to the cysteinyl-containing LTC4 by LTC4 
synthase (LTC4S), which can be metabolized to LTD4 and LTE4. Biosynthesis of prostanoids begins with the enzyme cyclooxygenase (COX)-1 or COX-2 converting 
AA to prostaglandin (PG) H2, which is further converted to a variety of other prostanoids. Thromboxane A2 (TXA2) is generated by TXA synthase (TXAS), while the 
synthases PGxS produce the certain PGs: PGF2α, PGI2, and PGD2. The microsomal PGE synthase-1 (mPGES-1) catalyzes formation of PGE2.
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begins with the release of AA from the cell membrane by 
phospholipase A2 which is followed by the metabolism of the AA 
through cyclooxygenases (COXs), lipoxygenases (LOXs), and 
cytochrome P450 enzymes (Wang and Dubois, 2010). Due to 
the key role of these enzymes in the formation of bioactive lipid 
mediators, it is not surprising that 5-LO and COX enzymes are 
prominent miRNA targets (for previous reviews, see also Ochs 
et al., 2011; Ochs et al., 2014).
MIRNA REGULATION IN PROSTANOID 
BIOSYNTHESIS
The group of prostanoids consists of prostaglandins, thromboxane 
A2, as well as prostacyclin. Their common denominator is 
that they can all be formed from AA, which is converted by 
COX enzymes in a two-step process to PGH2 (Figure 2). This 
intermediate is then converted to the different prostaglandins 
by the respective synthases. Prostanoids belong to the most 
important inflammatory signaling molecules. These lipid 
mediators exert their multiple biological effects in an autocrine 
and paracrine manner by binding to their specific cell surface 
G protein-coupled receptors. For example, prostaglandin E2 
(PGE2) is a bioactive lipid that can elicit a wide range of biological 
effects associated with inflammation and cancer (Jakobsson et al., 
1999; Pettersson et al., 2005; Nakanishi and Rosenberg, 2013). 
It contributes to the development of inflammation and plays a 
predominant role in promoting cancer progression by induction 
of cellular proliferation and tumor angiogenesis, inhibition of 
apoptosis, and suppression of immune responses (Wang and 
Dubois, 2006; Larsson and Jakobsson, 2015). PGE2 is formed by 
the conversion of AA to PGH2 by the cyclooxygenases COX-1 
or COX-2, followed by processing by PGE synthases, of which 
microsomal prostaglandin E synthase 1 (mPGES-1) is the key 
enzyme. The formed PGE2 is then rapidly secreted to act on 
their specific receptors on recipient cells. These receptors are not 
only present on immune cells, but also on a variety of cells of the 
cardiovascular system like cardiomyocytes, smooth muscle cells, 
or vascular endothelial cells (Suzuki et al., 2011). Thus, PGE2 
can be involved in the development of different cardiovascular 
diseases. It was shown that deletion of mPGES-1 impairs the left 
ventricular contractile function after acute myocardial infarction 
and leads to overall remodeling of the left ventricle (Degousee 
et  al., 2008).
Non-Canonical miRNA Regulation of 
Prostaglandin E2 Biosynthesis
A variety of cancer types exhibit increased levels of mPGES-1 and 
its enzymatic product PGE2—for example, colon (Yoshimatsu 
et al., 2001b; Wang and Dubois, 2010), prostate (Jain et al., 2008; 
Hanaka et al., 2009), lung (Yoshimatsu et al., 2001a), and breast 
cancer (Olesch et al., 2015). Interestingly, there were marked 
differences in the extent of upregulation of mPGES-1 and PGE2 in 
individual lung tumors (Yoshimatsu et al., 2001a; Wu et al., 2010). 
This effect can be attributed to individual expression variations 
of COX-2 and mPGES-1 (Wang et al., 2006; Hughes et al., 2008). 
However, the observed variability cannot be explained solely 
by different transcriptional regulation mechanisms [such as 
nuclear factor κB (NFκB)] (Yamamoto et al., 1995; Kang et al., 
2007), suggesting that additional—namely, post-transcriptional 
mechanisms—might be involved—for instance, miRNA regulation.
Recently, we demonstrated that miR-574-5p activates mPGES-
1-derived PGE2 synthesis in human non-small cell lung cancer 
(NSCLC). Moreover, this miRNA promotes tumor growth in 
vivo, which is completely blocked by the administration of the 
mPGES-1 inhibitor CIII (Leclerc et al., 2013). Mechanistically, 
it could be shown that miR-574-5p acts as RNA decoy to CUG-
RNA-binding protein 1 (CUGBP1) (Figures 1C, 3A) and that 
it antagonizes the CUGBP1 function as a post-transcriptional 
regulator (Mukhopadhyay et al., 2003; Subbaramaiah et al., 2003; 
Gao et al., 2015). In human, NSCLC as well as under inflammatory 
conditions, miR-574-5p is strongly upregulated and induces 
mPGES-1 expression by preventing CUGBP1 binding to the 
mPGES-1-3´UTR. This leads to an enhanced alternative splicing 
and the generation of a 3´UTR splice variant. Importantly, the 
nuclear localization of miR-574-5p and CUGBP1 is in line with 
its regulatory function on mPGES-1 mRNA splicing (Saul et al., 
2019). The newly discovered association between miR-574-5p 
overexpression and PGE2-mediated growth of lung cancer cells in 
vivo suggests that pharmacological inhibition of PGE2 formation 
with mPGES-1 or COX inhibitors might be of considerable 
therapeutic value for NSCLC patients with high miR-574-5p 
levels (Saul et al., 2019). In this respect, mPGES-1 inhibition 
might be of particular interest since inhibition of mPGES-1, 
instead of COX-2, may be associated with fewer side effects as 
other prostanoids would not be affected.
Canonical miRNA Regulation of 
Prostaglandin Biosynthesis
There are two known isoenzymes responsible for the generation 
of prostanoids: cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
(COX-2), both of which catalyze the same enzymatic reaction. 
COX-1 represents a housekeeping enzyme responsible for 
maintaining basal prostanoid levels, which are important for 
tissue homeostasis. In contrast, COX-2 is barely detectable in most 
normal tissues, but is strongly induced in response to inflammatory 
cytokines, hypoxia, and other stressors (Samuelsson et al., 2007; 
Wang and Dubois, 2010).
COX-2 expression is regulated at different levels (Dixon 
et al., 2000; Harper and Tyson-Capper, 2008). Various 
transcription factors such as NFκB, activator protein 1 (AP1), 
or the cAMP-responsive element-binding protein (CREB) are 
involved in its transcriptional regulation (Yamamoto et al., 
1995; Kang et al., 2007).
At the post-transcriptional level, COX-2 expression is 
regulated by mRNA stability and translation efficiency mostly 
including trans- and cis-acting factors (Dixon et al., 2000; 
Young and Dixon, 2010). For example, RNA-binding proteins 
can interact with AU-rich elements (AREs) within the 
COX-2 3´UTR like CUG triplet repeat-RNA-binding protein 
2 (CUGBP2) (Mukhopadhyay et al., 2003) or the mRNA-
stability factor HuR (Erkinheimo et al., 2003; Subbaramaiah 
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et al., 2003). Tristetraprolin (TTP), another RNA-binding 
protein that promotes mRNA instability, has been shown to 
bind to the 3´UTR of COX-2 and thus contributes to the post-
transcriptional regulation of COX-2 (Sawaoka et al., 2003). In 
addition, the use of an alternative polyadenylation signal may 
regulate COX-2 mRNA stability and translation (Hall-Pogar 
et al., 2005; Hall-Pogar et al., 2007).
In recent years, miRNAs have been identified as additional 
players in the post-transcriptional control of COX-2 expression 
(see Table 1). Interestingly, miR-16 is complementary to 
sequences in the AU-rich regions of the COX-2 3’UTR, which 
allows direct binding of miR-16, and in turn, alters COX-2 mRNA 
stability (Jing et al., 2005) (Figure 3). In association with TTP, 
miR-16 can promote mRNA decay. However, TTP does not bind 
directly to miR-16 but interacts through the association with 
RISC components to form a complex with miR-16 and promote 
mRNA degradation (Jing et al., 2005). Furthermore, miR-16 
silences COX-2 expression in hepatoma cells via two mechanisms: 
by binding directly to the COX-2 3′-UTR and by decreasing the 
levels of the RNA-binding protein HuR (Agra Andrieu et al., 2012) 
(Figure 3B). MiR-16 also competes with the RNA-binding protein 
heterogeneous nuclear ribonuclear protein K (hnRNP K) for 
binding to COX-2 3´UTR and thus modulates COX-2 expression 
on the post-transcriptional level (Shanmugam et al., 2008).
In addition, a considerable number of reports focus on miR-144, 
which directly targets COX-2 mRNA to downregulate its protein 
level. For example, the balance between miR-144, COX-2, and 
c-fos regulates PGE2 synthesis in the amnion of pregnant humans 
and mice. The amnion is the major source of PGE2 and plays a 
central role in the process of premature labor. The transcription 
factor c-fos induces expression of COX-2 and miR-144. The 
latter in turn generates a negative feedback loop by directly and 
indirectly inhibiting both COX-2 and c-fos. This inhibition has a 
negative effect on PGE2 generation and thus prevents premature 
contractions (Li et al., 2016). A negative correlation of miR-144-5p 
and COX-2 was also observed in human inflamed gingival tissue 
from periodontitis patients (Li et al., 2019). Moreover, a significant 
downregulation of miR-144 and miR-26a compared to healthy 
surrounding tissue was found in the tumor tissue of patients with 
esophageal squamous cell carcinoma (ESCC). The two miRNAs 
were confirmed to bind to COX-2 mRNA, thus downregulating 
the protein level of COX-2. It has been shown that, due to 
downregulation of miR-144 and miR-26a in tumor tissue, COX-2 
activity significantly increased and subsequently promoted cell 
proliferation and metastasis (Shao et al., 2016). COX-2 is also a 
canonical target of miR-101-3p that is downregulated in ESCC 
cells stimulated with cigarette smoking extract (CSE). It has been 
shown that the promoting effect of CSE on ESCC is due to COX-2 
upregulation. It was further demonstrated that the mechanism 
by which CSE regulates COX-2 expression is mediated by miR-
101-3p to promote cell proliferation (Gong et al., 2016). Another 
miRNA that regulates COX-2 via its canonical function is miR-
146a, a miRNA that is regulated like COX-2 by NFκB signaling 
(Poligone and Baldwin, 2001; Taganov et al., 2006). In human 
lung cancer, miR-146a directly regulates COX-2 mRNA and thus 
the protein level of COX-2 in lung cancer cells (Cornett and Lutz, 
2014) (Figure 3C). In human fibroblasts of smokers with chronic 
obstructive pulmonary disease, it was found that single nucleotide 
polymorphisms in the miR-146a precursor caused several patients 
to have reduced miRNA level, which significantly improved 
baseline lung function (Wang et al., 2015). Very recently, it was 
demonstrated that the polymorphisms of miR-146a (rs2910164) 
and plasmacytoma variant translocation 1 (PVT1; rs13281615) 
affect the prognosis of colon cancer by regulating COX-2 
FIGURE 3 | Regulatory circuits of leukotriene and prostaglandin biosynthesis. (A) miR-574-5p/CUGBP1 regulates mPGES-1 level, (B) miR-16/HuR and 
(C) miR-146a modulate COX-2 expression. (D) miR-125 and (E) miR-19a regulate 5-LO level. Stimulation is indicated by blue arrows, whereas red lines 
indicate inhibition.
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expression and cell apoptosis. The presence of PVT1 decreased 
the expression level of miR-146a, which in turn increased the 
COX-2 level (Zhang et al., 2019). Another miRNA that suppresses 
inflammation-related tumors is miR-30a. MiR-30a is crucial for 
regulation of growth and migration of Heliobacter pylori–infected 
gastric cancer via targeting COX-2 and B cell CLL/lymphoma 9 
(BCL 9) (Liu et al., 2017). In the same way, colorectal cancer is 
influenced by miR-216a-3p, which directly targets COX-2 via its 
canonical function (Wang et al., 2018).
In addition to the miRNA regulation of enzymes involved in 
PGE2 formation like COX-2 and mPGES-1, it is important to explore 
how the PGE2-metabolizing enzyme is regulated by miRs. The key 
enzyme that converts PGE2 to its biologically inactive metabolite 
is the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase 
(15-PGDH/HPGD) (Ensor and Tai, 1995). In cholangiocarcinoma 
cells, 15-PGDH was identified as a direct target of miR-21. In 
addition, COX-2 overexpression and PGE2 treatment increase 
the level of miR-21 associated with enhanced miR-21 promoter 
activity (Lu et al., 2014). The finding that miR-21 directly regulates 
15-PDGH was further confirmed by recent publications on tongue 
squamous cell carcinoma (He et al., 2016), gastric cancer (Li et al., 
2019) and colon cancer (Monteleone et al., 2019). Interestingly, 
epithelial growth factor (EGF) signaling in colorectal cancer cells 
reduces the level of 15-PGDH and simultaneously increases the 
miR-21 level (Monteleone et al., 2019).
In addition to this, other miRNAs are known to modulate 
15-PGDH expression. Omega-3 polyunsaturated fatty acids (ω-3 
PUFA) upregulate 15-PGDH expression by inhibiting miR-26a 
and miR-26b. This directly contributes to ω-3 PUFA-induced 
inhibition of human cholangiocarcinoma cell growth, providing 
TABLE 1 | Summary—miRNAs influencing the prostaglandin pathway by binding to mRNAs of key enzymes or interfering with RNA-binding protein CUGBP1 (see 
mPGES-1).
miRNA Target Tissue/disease Reference
Hsa-miR-144 COX-2 Premature labor (Li et al., 2016)
Hsa-miR-144-5p COX-2 Periodontitis (Li et al., 2019)
Hsa-miR-144 COX-2 Esophageal squamous cell cancer (Shao et al., 2016)
Hsa-miR-26a
Hsa-miR-26b COX-2 Nasopharyngeal epithelial cancer (Ji et al., 2010)
Hsa-miR-26b COX-2 Oral lichen planus (Danielsson et al., 2012)
Hsa-miR-26b COX-2 Breast cancer (Li et al., 2013)
Hsa-miR-216a-3p COX-2 Colorectal cancer (Wang et al., 2018)
Hsa-miR-30a COX-2 Gastric cancer (Liu et al., 2017)
Hsa-miR-146a mPGES-2 Bone marrow-derived mesenchymal 
stem cells
(Matysiak et al., 2013)
Hsa-miR-146a COX-2 COPD (Sato et al., 2010)
Hsa-miR-146a COX-2 Astrocytes (Iyer et al., 2012)
Hsa-miR-146a COX-2 Colon cancer (Zhang et al., 2019)
Hsa-miR-146a COX-2 Lung cancer (Cornett and Lutz, 2014)
Hsa-miR-146a COX-2 COPD (Wang et al., 2015)
Mmu-miR-199a COX-2 Mouse uterus, endometrial cancer (Chakrabarty et al., 2007; Daikoku 
et al., 2008)Mmu-miR-101a
Hsa-miR-101 COX-2 Colon cancer (Strillacci et al., 2009)
Hsa-miR-101 COX-2 Endometrial serous carcinoma (Hiroki et al., 2010)
Hsa-miR-101a COX-2 Mammary gland (Tanaka et al., 2009)
Hsa-miR-101 COX-2 Gastric cancer (He et al., 2012)
Hsa-miR-101 COX-2 Prostate cancer (Hao et al., 2011)
Hsa-miR-101-3p COX-2 Esophageal squamous cell cancer (Gong et al., 2016)
Hsa-miR-16 COX-2 Cervical cancer (Jing et al., 2005)
Hsa-miR-16 COX-2 Hepatocellular carcinoma (Agra Andrieu et al., 2012)
Hsa-miR-16 COX-2 Monocytes (THP-1 cells) (Shanmugam et al., 2008)
Hsa-miR-137 COX-2 Glioma (Chen et al., 2012)
Hsa-miR-143 COX-2 Amnion mesenchymal cells (Kim et al., 2011)
Hsa-miR-542-3p COX-2 Colon cancer (Moore et al., 2012)
Hsa-miR-574-5p mPGES-1 Lung cancer (NSCLC) (Saul et al., 2019)
Hsa-miR-21 15-PGDH Cholangiocarcinoma (Lu et al., 2014)
Hsa-miR-21 15-PGDH Tongue squamous cell cancer (He et al., 2016)
Hsa-miR-21 15-PGDH Gastric cancer (Li et al., 2019)
Hsa-miR-21 15-PGDH Colon cancer (Monteleone et al., 2019)
Hsa-miR-26a/b 15-PGDH Cholangiocarcinoma (Yao et al., 2015)
Hsa-miR-620 15-PGDH Prostate adenocarcinoma cell line 
(DU145); breast cancer cell line 
(MDA-MB-231)
(Huang et al., 2015)
Hsa-miR-218 15-PGDH Synovial mesenchymal stem cells 
(SMSCs)
(Cong et al., 2017)
Hsa-miR146b-3p 15-PGDH Cervical cancer (Yao et al., 2018)
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a preclinical justification for the evaluation of ω-3 PUFA in 
the treatment of cholangiocarcinoma (Yao et al., 2015). MiR-
620 directly targets 15-PGDH, which results in an increase in 
PGE2 promoting radioresistance in cancer cells like the human 
prostate adenocarcinoma cell line DU145 and the breast cancer 
cell line MDA-MB-231 (Huang et al., 2015). Furthermore, miR-
218 directly regulates the expression level of 15-PGDH during 
differentiation of synovial mesenchymal stem cells (SMSCs) 
into cartilage and subsequently inhibits osteogenesis during 
chondrogenesis (Cong et al., 2017). Finally, 15-PDGH was 
identified as the canonical target of miR-146b-3p that promotes 
proliferation, migration, and anchorage-independent growth of 
cervical cancer cells (Yao et al., 2018).
Influence of the Prostaglandin Pathway 
on miRNA Expression
In addition to the regulation of the enzymes of the prostaglandin 
pathway by miRNAs, the influence of prostaglandin signaling on 
miRNA expression has also been investigated. It was found that 
COX-2 signaling increases the oncogenic miR-526b and miR-
655 levels in human breast cancer by activating the EP4 receptor. 
Thus, COX-2 signaling strongly influences the phenotype of the 
tumor by promoting cellular migration, invasion, or proliferation 
(Majumder et al., 2015; Majumder et al., 2018).
In addition, it was found that cancer-associated fibroblasts 
(CAFs) develop a senescence-associated secretory phenotype 
(SASP) that contributes to cancer progression. Interestingly, 
senescent CAFs have increased levels of PGE2 and COX-2. 
Moreover, miR-335 is upregulated in the senescent normal 
fibroblasts as well as CAFs. This modulates the secretion of SASP 
factors and induces the mobility of cancer cells in co-cultures, at 
least partially by suppressing the expression of the phosphatase 
and tensin homologue (PTEN). With the application of the COX-2 
inhibitor celecoxib, expression of miR-335 was strongly reduced, 
suggesting a new miR-335/COX-2/PTEN axis that modulates the 
inflammasome in senescent fibroblasts (Kabir et al., 2016).
In line with these results, it was demonstrated that the 
mPGES-1/PGE2 pathway affects the expression level of miR-
15a and miR-186 in prostate cancer. High PGE2 levels reduced 
Dicer expression and consequently miRNA biogenesis in 
prostate cancer cells. It is noteworthy that PGE2-mediated 
downregulation of miR-15a and miR-186 is directly associated 
to vascular endothelial growth factor (VEGF) expression and 
angiogenesis. This suggests that these miRNAs may be potential 
candidates for mitigating the aggressive properties of prostate 
cancer. This alternative approach could overcome the chemo-
resistance, which is common for drugs targeting VEGF and/or 
VEGF receptors (Terzuoli et al., 2016).
MIRNA REGULATION IN LEUKOTRIENE 
BIOSYNTHESIS
The 5-lipoxygenase (5-LO) is the key enzyme of the leukotriene 
pathway. It interacts with the 5-LO-activating protein (FLAP) and 
catalyzes the conversion of AA into 5(S)-hydroperoxyeicosatetraenoic 
acid (5-HPETE) and leukotriene (LT) A4. The LTA4 is then 
subsequently converted either into biologically active LTB4 by LTA4 
hydrolase or into LTC4 by LTC4 synthase and the LTC4 synthase 
isoenzyme MGST2. Over the last decades, different studies have 
shown that 5-LO-derived AA metabolites play an important role 
in inflammatory reactions like inflammatory disorders and allergic 
diseases such as asthma, allergic rhinitis, cardiovascular diseases, as 
well as in different types of cancer (Steinhilber and Hofmann, 2014).
Canonical miRNA Regulation 
on Leukotriene Pathway
In contrast to COX-2, the knowledge about post-transcriptional 
regulation of 5-LO is rather limited. It is known that the combination 
of alternative splicing and RNA decay modulates 5-LO gene 
expression (Ochs et al., 2012). Furthermore, several publications 
demonstrated that 5-LO is a canonical target for miR-19a-3p, miR-
125-5p (Busch et al., 2015), miR-216-3p (Wang et al., 2018), and 
miR-674-5p (Su et al., 2016) (see Table 2). Specifically, miR-19a-3p 
and miR-125-5p regulate 5-LO expression in the human myeloid 
cell line MonoMac 6. In contrast, only miR-19a-3p modulates 
the 5-LO protein level in human T-lymphocytes stimulated with 
phytohemagglutinin (PHA). Overall, it reveals that miR-19a-3p 
and miR-125b-5p target 5-LO in a cell type and stimulus-specific 
manner (Busch et al., 2015). Interestingly, miR-125 and miR-19a 
seem to be parts of regulatory circuit-controlling immune reactions 
and cell proliferation (Figures 3D, E). 5-LO expression is induced 
by TLR/NFκB activation (Lee et al., 2015) or during cell stimulation 
by transforming growth factor (TGF)-β (Steinhilber et al., 1993). 
The same signals were also reported to induce miR-125 (Curtale 
et al., 2018; Hildebrand et al., 2018) as well as miR-19a, which in 
turn downregulates components of NFκB or TGF-β signaling, 
respectively, and also 5-LO (Figures 3D, E) (Dews et al., 2010; Busch 
TABLE 2 | Summary—miRNAs influencing the leukotriene pathway by binding to mRNAs of key enzymes.
miRNA Target Tissue/disease Reference
Hsa-miR-19a-3p 5-LO Monocytes (MM6 cells), 
T-lymphocytes
(Busch et al., 2015)
Hsa-miR-125-5p
Hsa-miR-674-5p 5-LO Acute mouse liver injury (Su et al., 2016)
Hsa-miR-216a-3p 5-LO Colorectal cancer (Wang et al., 2018)
Hsa-miR-146a FLAP Lung cancer (Iacona et al., 2018)
Hsa-miR-135a FLAP Pulmonary microvascular 
endothelial cells
(Gonsalves and Kalra, 2010)
Hsa-miR-199a
MiRNA Regulation in Cancer and InflammationSaul et al.
8 July 2019 | Volume 10 | Article 824Frontiers in Pharmacology | www.frontiersin.org
et al., 2015). Thus, upregulation of miR-19a and downregulation 
of 5-LO expression are associated with cell proliferation in 
T-lymphocytes (Busch et al., 2015). Furthermore, it is well known 
that upregulation of miR-19a inhibits cell differentiation and 
promotes cell growth and cancer development—for instance, by 
suppression of PTEN (Lewis et al., 2003). MiR-674-5p was identified 
as a direct regulator of 5-LO mRNA in mice. It is further discussed as 
a negative regulator in 5-LO-mediated autoimmune diseases of the 
liver, thus representing a promising approach to future therapeutic 
measures (Su et al., 2016). Recently, it was shown that miR-216a-3p 
regulates not only COX-2 but also 5-LO expression in colon cancer, 
thus affecting colon cancer cell proliferation. These data indicate 
that miR-216-3p might represent a novel target for colorectal cancer 
treatment (Wang et al., 2018). Interestingly, not only 5-LO but also 
FLAP is targeted by miRs, like miR-146a in human lung cancer 
(Iacona et al., 2018). Moreover, miR-146a is also known to regulate 
COX-2 expression in lung cancer (Cornett and Lutz, 2014), which 
indicates a role of miR-146a as an endogenous dual inhibitor of AA 
metabolism in lung cancer by regulating prostaglandins and LTs, 
similar to miR-216a-3p (Iacona et al., 2018).
Influence of the Leukotriene Pathway on 
miRNA Expression
It is well known that 5-LO interacts with the C-terminal domain of 
human Dicer. The interaction between 5-LO and Dicer leads to an 
enhanced 5-LO enzymatic activity as well as Dicer activity in vitro. 
These results suggest that the processing of specific miRNAs by 
Dicer might be regulated by the 5‐LO/Dicer interaction (Dincbas-
Renqvist et al., 2009). In addition to the direct 5-LO/Dicer 
interaction, 5-LO products can also modulate miRNA expression. 
Thus, LTB4 induces the expression of inflammatory miRNAs 
including miR-155, miR-146a and miR125b in macrophages via 
the LT B4 receptor-1 (BLT1) and Gα1 signaling (Wang et al., 2014).
CONCLUSIONS
The number of miRNAs that were discovered in recent years to 
be involved in the regulation of the expression of key enzymes in 
prostanoid and LT biosynthesis is steadily increasing. Tables 1, 2 
give a comprehensive overview of all currently known miRNAs 
involved in inflammatory processes. There is growing evidence 
that many of these miRNAs are involved in complex regulatory 
cascades and networks with multiple layers of integrated signals 
and feedback loops required for fine-tuning of biological functions 
such as inflammatory responses or cell growth. Besides the direct, 
canonical regulation of mRNA stability and translation of enzymes 
of the AA cascade by miRNAs, it was found that miRNAs that 
interfere with HUR or TTP function are involved in the regulation 
of COX-2 expression. Furthermore, a novel non-canonical 
mechanism was found for miR-574-5p, which acts as a decoy for 
CUGBP1 and strongly stimulates PGE2 formation. It becomes clear 
that miRNAs can also be packed into EVs so that they are involved 
in cell–cell communication. This suggests that miRNAs not only 
regulate cellular functions in an autocrine/intracrine manner but 
also can affect processes such as the formation of lipid mediators 
in a paracrine fashion. Of note, 5-LO was identified as a binding 
protein for Dicer, which suggests that 5-LO can modulate the Dicer 
function and interferes with miRNA generation. Thus, it becomes 
increasingly clear that there are multiple links between the miRNA 
network and lipid signaling. The progress in the understanding of 
these interactions will help to develop new therapeutic strategies 
for the treatment of inflammatory diseases and cancer.
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